Cutaneous adverse effects of the available <scp>COVID</scp>‐19 vaccines in India: a questionnaire‐based study

Bawane, Jai; Kataria, Rajesh; Mohite, Anil; Verma, Kapila; Shukla, Utkarsh

doi:10.1111/jdv.18150

Cited by 10 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, injection site pain was more common after Covaxin than the other vaccines considered in our study. This outcome is consistent with the findings of another study comparing Covaxin with Covishield [56] .…”

Section: Discussionsupporting

confidence: 92%

Side effects of Sputnik V, Oxford–AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran

Oghazian

Tamanaei

Haghighi

et al. 2023

International Immunopharmacology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Side effects of Sputnik V, Oxford–AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran

Oghazian

Tamanaei

Haghighi

et al. 2023

International Immunopharmacology

View full text Add to dashboard Cite

“…We read with great interest the article recently published by Bawane et al . reporting the results of a questionnaire‐based study investigating the cutaneous adverse events (AEs) related to the available COVID‐19 vaccines in India in healthcare workers, 2 and we also want to report our experience regarding the development of cutaneous reactions following Covid‐19 vaccination in patients attending our department. A retrospective study was conducted on data collected from patients attending our Dermatology Department for the development of skin manifestations related to Covid‐19 vaccination.…”

Section: Tablementioning

confidence: 99%

Reply to ‘Cutaneous adverse effects of the available COVID‐19 vaccines in India: A questionnaire‐based study’ by Bawane J et al.

Potestio

Genco

Villani

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…We summarized major findings of the cutaneous reactions’ duration in Table S6 in the Online Supplementary Document . Five studies [ 23 , 24 , 27 , 32 , 45 ] reported the duration of local injection site reactions, with observed discrepancies across studies. Overall, the median duration ranged from one day to 4.5 days [ 23 , 27 , 32 ]; more than 80% of participants showed duration of <3 days [ 44 ].…”

Section: Resultsmentioning

confidence: 99%

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Understanding the incidence pattern of cutaneous reactions is crucial for promoting COVID-19 vaccination. We aimed to report the global incidence pattern of, and factors associated with common cutaneous reactions related to COVID-19 vaccination in real-world settings. Methods We searched five databases (PubMed, Web of Science, Embase, CNKI, and Wanfang) from inception to May 13, 2022, for studies reporting the incidence of common cutaneous reactions related to COVID-19 vaccines in real-world settings. The outcomes were the systematic skin reactions (rash and urticaria) and the local injection site reactions (pain, swelling, redness, and erythema). We conducted random-effects meta-analyses and explored associated factors using multi-step statistical analyses. Results We included 35 studies and assessed 2 549 968 participants from 23 countries. The pooled incidence of overall systemic skin reactions was 3.8% (95% confidence interval (CI) = 2.4%-5.5%) with short duration (about one week). Specifically, the pooled incidence rates of rash and urticaria were 3.0% (95% CI = 2.1%-3.9%) and 1.1% (95% CI = 0.7%-1.5%), respectively. For overall local injection site reactions, the pooled incidence was 72.4% (95% CI = 65.7%-78.7%) with short duration (1 to 4.5 days). Except for local pain (72.2%, 95% CI = 65.3%-78.5%), other localized reactions had low incidence, including swelling (13.3%, 95% CI = 9.5%-17.7%), redness (11.5%, 95% CI = 5.7%-19.0%), and erythema (5.8%, 95% CI = 0.7%-15.4%). Geographically, different distribution patterns were observed for these reactions. Regarding associated factors, mRNA vaccines showed lower incidence of urticaria ( P < 0.001). Asia population showed higher incidence of urticaria ( P < 0.001). We observed lower incidence rates of overall local injection site reactions and pain among inactivated vaccines ( P < 0.001). We found no significant difference among reactions between the first and the second dose of vaccines. Conclusions We examined the global incidence pattern of common cutaneous reactions related to COVID-19 vaccination and found low incidence and short duration of systemic skin reactions and local injection site reactions (except for pain); discrepancies in these reactions were observed across different vaccine types. The cutaneous side effects related to COVID-19 vaccination do not seem to cause concern. Registration PROSPERO: CRD42021258012.

show abstract

Cutaneous adverse effects of the available COVID‐19 vaccines in India: a questionnaire‐based study

Cited by 10 publications

References 8 publications

Side effects of Sputnik V, Oxford–AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran

Side effects of Sputnik V, Oxford–AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran

Reply to ‘Cutaneous adverse effects of the available COVID‐19 vaccines in India: A questionnaire‐based study’ by Bawane J et al.

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

Contact Info

Product

Resources

About